

# SEE INSIDE FOR THE FULL PROGRAM! 26-28 January, The Grand Hyatt, Washington, DC

Running concurrently with the **Cell & Gene Therapy Forum 2009**

Phacilitate   
**VACCINE FORUM**  
WASHINGTON 2009  
www.phacilitate.co.uk/wv



## Driving Progress

Attend the Washington Vaccine Forum 2009 to learn from – and meet – 70+ high profile speakers, including:

- **Dr Mikael Dolsten**, President, Research & Development, Wyeth Pharmaceuticals, Senior Vice President, Wyeth Corporation
- **Dr Michel De Wilde**, Senior Vice President, Research & Development, sanofi pasteur
- **Dr Robin Robinson**, Director, Biomedical Advanced Research & Development Authority (BARDA), Office of the Assistant Secretary for Preparedness & Response (ASPR), US Department of Health & Human Services
- **Dr Gary J. Nabel**, Director, Vaccine Research Center, National Institute of Allergy & Infectious Diseases (NIAID), NIH
- **Anne Schuchat, MD, RADM**, US Public Health Service, Assistant Surgeon General, Director, National Center for Immunization & Respiratory Diseases, Centers for Disease Control & Prevention
- **Dr Robert Kadlec**, Special Assistant to the President for Homeland Security & Senior Director for Biological Defense Policy
- **Dr Allan P. Jarvis**, Senior Vice President, Corporate Development, sanofi pasteur
- **Dr Norman W. Baylor**, Director, Office of Vaccines Research & Review (OVRR), CBER, US Food & Drug Administration
- **Peter Ehrenheim**, President & CEO, GE Healthcare Life Sciences
- **Hartmut J. Ehrlich, MD**, Vice President, Global R&D, Baxter BioScience
- **Drs Ben Machielse**, Executive Vice President, Operations, MedImmune, Inc
- **Carl W. Dieffenbach, PhD**, Director of the Division of AIDS (DAIDS), National Institute for Allergies & Infectious Diseases (NIAID), NIH
- **Dr John W. Shiver**, Vice President, Worldwide Basic Research Franchise Head, Vaccines, Merck Research Laboratories
- **Dr Karen J. Huebscher**, Global Head of Business Development & Licensing, Novartis Vaccines and Diagnostics
- **Vijay B. Samant**, President & CEO, Vical, Inc

- **Dr Keith Gottesdiener**, Vice President & Head of Clinical Vaccines & Infectious Diseases, Merck Research Laboratories
- **Dr Michael V. Callahan**, Program Manager, Rapid Vaccine Assessment (RVA), Defense Advanced Research Projects Agency (DARPA)
- **Dr Jerald C. Sadoff**, President & CEO, Aeras Global TB Vaccine Foundation
- **Dr Douglas J. Pon**, Assistant Vice President, Vaccine Licensing, Global Business Development, Wyeth Pharmaceuticals
- **Heather L. Davis, PhD**, Executive Director, Pfizer Global R&D, Vaccines Research, Site Head, Ottawa Laboratories
- **Christian Mandl, MD, PhD**, Vice President & Global Head of Virology, Head of Research, US, Novartis Vaccines and Diagnostics, Inc
- **Bill Helming**, Vice President, Biodefense & Public Health Practice, PRTM Management Consultants LLC
- **Elisabeth Lindner**, CEO & President, Diamyd Medical AB
- **Dr James Jackson**, Chief Scientific Officer, Emergent Biosolutions
- **Thomas E. Shrader, PhD, CFA**, Managing Director, Healthcare Research, Rodman & Renshaw, LLC
- **Robert V. House, PhD**, President, DynPort Vaccine Company, LLC, Frederick, MD
- **Dr Una S. Ryan**, Former CEO of AVANT Immunotherapeutics
- **Dr Gregory M. Glenn**, Chief Scientific Officer, Intercell USA, Inc
- **Dr Michael G. Kurilla**, Director, Office of BioDefense Research Affairs, Associate Director for BioDefense Product Development, DMID, NIAID, NIH, DHHS
- **Dr Jeffrey Schlom**, Chief, Laboratory of Tumor Immunology & Biology, Center for Cancer Research, National Cancer Institute

- **Dr Darrell R. Galloway**, Director, Joint Science & Technology Office, Chemical & Biological Defense Directorate, Defense Threat Reduction Agency, US Department of Defense
- **Dr Alan Carr**, Life Sciences Analyst, Needham & Company, LLC
- **Dr Shou-Bai Chao**, Vice President, Vaccines Manufacturing, MedImmune, Inc
- **Ian Sellick**, Marketing Director, Pall Life Sciences
- **Dr Mark Feinberg**, Vice President, Policy, Public Health & Medical Affairs, Merck Vaccine Division
- **Dr Clement Lewin**, Head, Strategic Immunization Planning, Novartis Vaccines and Diagnostics
- **Alan S. Taggart**, Vice President, Government Project Management, MedImmune, Inc
- **Dr Suresh Jadhav**, Executive Director, Serum Institute of India Ltd
- **Dr Thomas P. Monath**, Partner, Kleiner Perkins Caufield & Byers
- **Dr John Boslego**, Director, Vaccine Development Global Program, PATH
- **Dr Stephen Lockhart**, Senior Vice President, Product Development, Emergent Biosolutions
- **Dr David L. Urdal**, CSO, Dendreon Corporation
- **Raafat E. F. Fahim, PhD**, President & CEO, Nabi Biopharmaceuticals
- **Dr Phillip Gomez**, Principal, PRTM
- **Dr Rahul Singhvi**, President & CEO, Novavax, Inc
- **Drew Hannaman**, Vice President, R&D, Ichor Medical Systems, Inc
- **Dr Christoph S. Klade**, Vice President, Technology Development & Clinical Immunology, Intercell AG
- **Dr Ian Henderson**, Chief Scientific Officer, DynPort Vaccine Company, LLC, Frederick, MD
- **Dr Tonya Villafana**, Director, Portfolio Management, PATH Malaria Vaccine Initiative (MVI)
- **Dr Luc Hessel**, Executive Director, Policy Affairs, Europe, sanofi pasteur MSD
- **Drs Manon Cox, MBA**, Chief Operating Officer, Protein Sciences Corporation

- **Dr Christopher D. Earl**, President & CEO, BIO Ventures for Global Health
- **Beth Wensley**, Vice President, Project Management, MedImmune, Inc
- **Shankar Musunuri, PhD, MBA**, Senior Director & Strategic Product Leader, Wyeth Biotech
- **Dr Jill Gilmour**, Senior Director, Clinical Immunology, International AIDS Vaccine Initiative
- **Professor Angus Dalgleish**, Professor of Oncology, St George's, University of London & Research Director, Onyxax Limited
- **Dr Charles Richardson**, Vice President, R&D, LigoCyte Pharmaceuticals, Inc
- **Dr Vidadi Yusibov**, Executive Director, Fraunhofer Center for Molecular Biotechnology
- **Dr Lou Cooper**, Past President, American Academy of Pediatrics (AAP)
- **Narender Dev Mantena**, Senior Vice President, Strategic Business Development, Biological E. Limited
- **Dr Ronald W. Ellis**, Senior Vice President & Chief Technical Officer, NasVax Ltd, Israel
- **Michael L. Dekleva, PhD**, Senior Director, World Wide Regulatory Affairs, Vaccines/Biologics, Merck & Co, Inc
- **Dr Helen McShane**, University of Oxford
- **Carla Botting**, Director, Quality Management & Commercial Affairs, PATH Malaria Vaccine Initiative (MVI)
- **Dr David Kirke**, Senior Consultant, ERA Consulting Group
- **Peter Zerhouni**, Director of Business Development, Diamyd Medical AB
- **Professor Dr Achim Schneeberger**, Head of Clinical Development, AFFIRIS GmbH
- **Dr Charles G. Drake**, Assistant Professor of Medical Oncology, Immunology & Urology, Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University
- **Wendy Taylor**, Vice President of Strategy & Operations, BIO Ventures for Global Health
- **Dr Janine T. Bryan**, Senior Research Fellow & HPV Lead, Department of Vaccines Basic Research, Merck Research Laboratories
- **Professor Steven J. Czinn**, Chair, Department of Pediatrics, University of Maryland School of Medicine

Gold sponsor:

Silver sponsors:

Bronze sponsors:



**REGISTER BEFORE  
FRIDAY 31st OCTOBER  
TO SAVE \$200!**

## REGISTRATION

### FEES

REGISTER BEFORE 31st OCTOBER 2008 AND SAVE \$200

All 3 days at the early bird rate  
\$2,465.00 £1,345.00

All 3 days after 31st October 2008  
\$2,665.00 £1,445.00

Academic/Government Rate  
\$1,425.00 £775.00

**Group Discount**  
Register 3 delegates and the 4th comes for free!  
Please e-mail us at team@phacilitate.co.uk to take advantage of this offer

Substantial discounts on the registration fee are available for representatives of small companies. For more information, please contact us on +44 (0)20 7839 6137 (team@phacilitate.co.uk)

If you would like to register for 1 or 2 days only, please e-mail team@phacilitate.co.uk and we will confirm the rate for you

To register for the Washington Vaccine Forum 2009, complete the form and:

+44 (0)20 7839 6533

+44 (0)20 7839 6137

Phacilitate Limited  
6, Excel Court, Whitcomb Street  
London WC2H 7ER, UK

or register on-line  
[www.phacilitate.co.uk/wv](http://www.phacilitate.co.uk/wv)

The registration fee includes all refreshments during the course of the conference, entrance to evening receptions, access to the Delegate Zone on the event website and full conference documentation. It does not include your accommodation.

**YOU WILL BE SENT YOUR USERNAME AND PASSWORD FOR THE DELEGATE ZONE ON THE WEBSITE ON RECEIPT OF YOUR PAYMENT. AT THIS STAGE, YOU WILL ALSO BE ABLE TO BOOK YOUR PLACES IN THE SESSIONS WITH LIMITED NUMBERS.**

**PLACES AT THESE SESSIONS WILL BE STRICTLY LIMITED AND WILL BE ALLOCATED ON A FIRST-COME-FIRST-SERVED BASIS.**

Delegate 1	Dr   Mr   Mrs   Ms   Miss <i>please indicate</i>
First Name	Second/Family Name
Position	
I would like to attend: All 3 days - Industry rate <input type="checkbox"/> All 3 days - Academic/Government rate <input type="checkbox"/>	
I have read and I DO NOT agree to Phacilitate's terms & conditions <input type="checkbox"/>	

**IF YOU ARE REGISTERING MORE THAN ONE DELEGATE PLEASE PHOTOCOPY THIS FORM.**

Organization	
Department	
Address	
State	
Postcode/Zipcode	Country
Telephone	Fax
e-mail	
Name of Assistant	Email
Approving Manager - Name	
Job Title	

**Payment | Payment must be received before the start of the conference in order to guarantee admittance.**

I would like to pay in <input type="checkbox"/> Dollars* <input type="checkbox"/> Sterling	Card no
* Credit card payments will all be processed in Sterling	Cardholder's name
I would like to pay by	Start date
<input type="checkbox"/> Crossed cheque payable to Phacilitate Limited	Expiry date
<input type="checkbox"/> Bank transfer (please see our bank details below)	Security Code:
<input type="checkbox"/> Credit card	Credit card billing address (if not as above)
<input type="checkbox"/> MasterCard <input type="checkbox"/> Visa <input type="checkbox"/> American Express	
<b>Bank details:</b>	Cardholder's signature
<b>Address:</b> HSBC plc, 85 Lewisham High Street, London, SE13 6BE, UK	
<b>For Dollar wire transfers:</b>	
Account no: 57139995 Sort Code: 40-05-15	
Swift Code: MIDLGB22	
IBAN: GB37MIDL40041541517104	
<b>For Sterling wire transfers:</b>	
Account no: 41517104 Sort Code: 40-04-15	
Swift Code: MIDLGB22	
IBAN: GB19MIDL40041541517104	
Please refer to the event code (PH136) and the delegate's name in the transfer instructions.	

ON RECEIPT OF YOUR REGISTRATION, WE WILL SEND YOU AN INVOICE/VAT RECEIPT. PHACILITATE WILL NOT BE HELD RESPONSIBLE FOR NON-RECEIPT OF YOUR REGISTRATION. IF YOU DO NOT RECEIVE YOUR CONFIRMATION, PLEASE CONTACT US TO ENSURE YOUR REGISTRATION HAS BEEN RECEIVED.

**The venue**  
Grand Hyatt Washington, 1000 H Street NW,  
Washington, DC, USA 20001  
Tel: +1 800 233 1234 Fax: +1 202 628 1641

**Accommodation**  
The conference fee does not include accommodation. We have negotiated substantially discounted rates for all attendees at the Washington Vaccine Forum at The Grand Hyatt Hotel. An accommodation booking form will be sent to you in your welcome pack, and you must use this form in order to qualify for the discounted rate which is only guaranteed for bookings received by the 5th of January 2009.

**Documentation**  
The conference documentation will be available on our website after the event for those individuals who cannot attend in person. If you are interested in receiving information on contents and cost in due course, please e-mail team@phacilitate.co.uk

**TERMS AND CONDITIONS**  
**Cancellation**  
a) If you cancel your place in writing at least 4 weeks from the event, you will be due a 75% refund of your fee.  
b) If you cancel your place in writing between 4 and 2 weeks of the event, you will be due a 50% refund of your fee.  
c) If you cancel your place within 2 weeks of the event, you will not be entitled to any refund, although you will be sent a copy of the documentation after the event. Please note that all conference fees remain payable, and invoices will not be cancelled, unless these cancellation terms are met.

**Replacement delegates**  
If you are unable to attend at any stage, you may transfer your registration to a colleague at no extra charge. Please confirm the details of the replacement in writing to team@phacilitate.co.uk (fax: +44 (0)20 7839 6533).

**Amendments to the program / Cancellation of the event**  
In the event of amendments being made to the conference agenda, they will be published on our website ASAP. However, we reserve the right to amend the programme content, timings or speakers without notice. In case of cancellation, our liability is limited to refund of registration fees only.

The Organiser shall not be liable for any failure or delay in performing any of its obligations if the failure or delay is due to any cause beyond its reasonable control, including unavailability of the venue of the Event, act of God, war, terrorist activity, civil commotion, malicious damage by a third party, strike, lock-out or other employee dispute, compliance with a law or governmental order, rule, regulation or direction, fire, flood or storm.

**Data Protection Act**  
Information which you provide or which is obtained in our dealings with you may be held by Phacilitate in accordance with the Data Protection Act and will be used by Phacilitate and its affiliates, agents and sub-contractors to provide the services and to enable us to review, develop and improve the services offered by us and to enable Phacilitate to provide you and other customers with relevant information through our marketing programme (including direct marketing). You further agree that information about you may be given to anyone to whom Phacilitate has assigned or transferred or proposes to assign or transfer any of its rights under this Agreement. You further agree that Phacilitate may use itself or disclose the information to any of its affiliates or other third parties for the marketing to you of other products and services (including direct marketing). If you do not wish us to use/disclose your details for such purposes you should tick this box.

**Amendments to our mailing list**  
If you would prefer not to receive any further materials from Phacilitate, please contact us and let us know your name, company and location. We guarantee you will be removed from our database immediately. Please also inform us in the same way if your details have changed or are currently incorrect. You can let us know by phone (+44 (0)20 7839 6137), e-mail (team@phacilitate.co.uk), fax (+44 (0)20 7839 6533) or mail (Phacilitate Limited, 6 Excel Court, Whitcomb Street, London WC2H 7ER, UK)

This contract is subject to English Law.

Phacilitate   
Phacilitate Limited, 6, Excel Court, Whitcomb Street, London WC2H 7ER, UK  
Tel: +44 (0)20 7839 6137 Fax: +44 (0)20 7839 6533 E-mail: team@phacilitate.co.uk  
[www.phacilitate.co.uk](http://www.phacilitate.co.uk)

7.30 Registration & buffet breakfast in the exhibition area

MORNING PLENARY SESSION

Delivering integrated business models for strategic growth for large and small companies in the sector

9.00 **Chair's introduction**  
**Analyst's introductory overview**  
**Dr Alan Carr**, Life Sciences Analyst, Needham & Company, LLC

9.20 **Big pharma perspective**

- How are we harnessing recent advances in technology and scientific understanding to build a portfolio robust enough to withstand the increasing economic pressures confronting the vaccine R&D model?
- What role will collaborative strategies play in shaping our future vaccines business model?
  - Innovation through acquisition: How are we seeking to retain the qualities of nimbleness and R&D innovation that attracted us initially to a recently acquired biotech company?
  - How do we cross-pollinate between vaccine and other divisions within the company?

**Dr Michel De Wilde**, Senior Vice President, Research & Development, sanofi pasteur

9.40 *Questions & discussion*

9.45 **Biotech perspective**  
**Examining the strategic growth choices open to biotech companies in the current economic climate**

- M&A, strategic partnering, acquiring technology from academia, etc: What blend is optimal?
- What innovative funding pathways will be available to smaller companies in future given the global credit crunch, and what are the keys to capitalizing on them?

**Vijay B. Samant**, President & CEO, Vical, Inc

10.05 *Questions & discussion*

10.10 **Status, trends and options for vaccine manufacturing**

- The vaccine market - a changing landscape
- Modern vaccine production challenges
- Possible GE Healthcare Life Sciences solutions to the challenges

**Peter Ehrenheim**, President & CEO, GE Healthcare Life Sciences

10.30 *Questions & discussion*

10.35 **Panel discussion**

- Moving forwards, what do we regard as being the key areas of opportunity on a global basis both in terms of disease targets and populations?
- What blend of pharma and biotech business models will work in the marketplace of the future, given the uniqueness of traditional market dynamics and commercial models in the vaccine area, or is a brand new model required as new technologies and targets emerge?

Panelist:  
**Dr Christopher D. Earl**, President & CEO, BIO Ventures for Global Health

11.00 *Morning coffee in the exhibition area*

FOLLOWED BY YOUR CHOICE OF 3 PARALLEL BREAKOUT SESSIONS:

FOCUS SESSION 1

**Vaccines at the tipping point: How and where will novel enabling technologies and a growing understanding of immunology lead us?**

- Weaving various value-adding technologies into a functional vaccine R&D platform

11.40 **Moderator's introduction**  
**VCs perspective: How do we currently assess novel technology platforms?**

- Key value drivers for investment
- Judging probability of commercial success
- The diligence process
- Forecasting financial and technical risk

**Dr Thomas P. Monath**, Partner, Kleiner Perkins Caufield & Byers

12.00 **Advancing vaccine development: Novel approaches to design and delivery**

- Rational design and technological advances in the generation of vaccines
- Integrating platforms and technologies: managing technical and regulatory hurdles
- Applying vaccine development techniques to evolving pandemics and emerging infections
- Initiating public/private partnerships for marketing and distribution

**Dr Gary J. Nabel**, Director, Vaccine Research Center, National Institute of Allergy & Infectious Diseases (NIAID), NIH

12.20 *Questions & discussion*

**Case studies**  
**Assessing recent clinical data from leading enabling technologies in development**

- What are the challenges in integrating them into functional platforms (particularly where multiple organizations are in collaboration) and how are they being addressed on an ongoing basis?

12.25 **Use of novel adjuvants in biodefense vaccines: A case study of AV7909**

**Dr James Jackson**, Chief Scientific Officer, Emergent Biosolutions

12.45 *Questions & discussion*

12.50 **Adjuvants and delivery systems: Combinations provide selective and synergistic enhancement of vaccine immunogenicity**

- Vaccine adjuvants may act primarily as a delivery system, primarily as an immune modulator, or have properties of both
- Use of different vaccine adjuvants and delivery systems in combination may have synergistic effects and allow for selective immune enhancement
- Good results are achieved by combining a delivery system with an immune modulator, or two immune modulators that act on different cells and/or pathways
- More is not always better – combining too many different adjuvants can be counterproductive

**Heather L. Davis, PhD**, Executive Director, Pfizer Global R&D, Vaccines Research; Site Head, Ottawa Laboratories

1.10 *Questions & discussion*

1.15 *Buffet lunch in the exhibition area*

OR **Working Lunch**

2.25 **Transcutaneous vaccination: The path to late-stage product development**

- Challenges in delivery of small amounts of large protein
- Travelers' diarrhea: Pathway to market
- Vaccine enhancement patch: Promise for one-dose pandemic influenza vaccine

**Dr Gregory M. Glenn**, Chief Scientific Officer, Intercell USA, Inc

2.50 *Questions & discussion*

2.55 **Electroporation based DNA vaccine delivery: Technology development and clinical progress**

- Implementation of clinical devices
- Results from immunogenicity and challenge studies in non-human primates
- Progress in the clinical evaluation of electroporation based DNA immunization for cancer and infectious disease indications

**Drew Hannaman**, Vice President, R&D, Ichor Medical Systems, Inc

3.15 *Questions & discussion*

3.20 **Adeno 35 and rdsRN chimeric viral vectors as platform delivery systems**

- These chimeric vectors are capable of inducing CD8+ T cell immunity (Ad35 demonstrated in humans)
- Ad35 and rdsRN can be given as aerosols for induction of cellular immunity in the lung
- rdsRN can be given orally
- rdsRN is extremely inexpensive to produce

**Dr Jerald C. Sadoff**, President & CEO, Aeras Global TB Vaccine Foundation

3.40 *Questions & discussion*

3.45 **Moderator's closing summary**

3.50 *Close of session followed by afternoon tea in the exhibition area*

FOLLOWED BY AFTERNOON PLENARY SESSION

1.15 **Working Lunch**  
**In light of recent setbacks with novel technologies, is it time to reassess the severity of safety concerns over 'tried and tested' technologies such as live attenuated vaccines?**

- Are these technologies still viable or not given the regulators' and the public's currently risk-averse view of vaccine safety? What could we be missing in side-lining traditional methods and technologies? (Very informal, highly interactive session for a maximum of 12 participants)

OR | FOCUS SESSION 2

**What benefits are single-use technologies and other novel vaccine manufacturing solutions providing in practice?**

- What savings are they delivering and how are the remaining technical and regulatory challenges being addressed?

11.40 **Moderator's introduction**  
**Upstream, downstream and even in final fill, new technologies are being developed apace. Universal panacea, pick and mix, or flash in the pan?**

- Brief review of technologies covered. What is truly new, what is not, and where are they proposed to be applied?
- How should you evaluate the effectiveness, robustness and ROI on a new technology?
- How acceptable are new technologies – to users and to regulators?
- What technologies are available at what scale: how easy is it to evaluate at the research and development level and propose scalable processes with confidence?
- Can you adopt technologies universally, choose certain of them and integrate with more traditional methods, or ignore them as too new and not suitable for the long-term?

**Ian Sellick**, Marketing Director, Pall Life Sciences

12.10 *Questions & discussion*

12.15 **Recent progress in the development of innovative and flexible low cost vaccine manufacturing solutions: Where is the technology today, and how might it transform the vaccine industry?**

- Can disposable technologies reduce the cost of development?
- What are the implications of increased productivity on the future of biopharma facilities?
- Can horizontal economies of scale accelerate the introduction of vaccines into the developing world?

**Dr Phillip Gomez**, Principal, PRM

12.40 *Questions & discussion*

**Case studies: Practical experiences with the utilization of novel manufacturing solutions**

- Assessing their performance**
  - In terms of cutting costs in general
  - In terms of accelerating the manufacturing process/boosting yield
  - In terms of delivering practical/logistical advantages (eg. flexibility in providing surge capacity)
  - In terms of their potential to reduce the QA burden and accelerate regulatory approval
- Why did we choose the technology/technologies in question and what challenges are we facing in terms of turning them into functional platforms?**

12.45 **Challenges and opportunities of live attenuated influenza vaccine: Manufacturer's perspective**

- Challenge of LAIV manufacturing: facility design, maintaining cold chain throughout manufacturing process
- Keep LAIV live: Stability
- Unpredictable market demand and supply
- Opportunity of LAIV for pandemic vaccine

**Dr Shou-Bai Chao**, Vice President, Vaccines Manufacturing, MedImmune, Inc

1.10 *Questions & discussion*

1.15 *Buffet lunch in the exhibition area*

OR **Working Lunch**

2.25 **Virus Like Particle vaccines for the emerging threat of norovirus**

**Dr Charles Richardson**, Vice President, R&D, LigoCyte Pharmaceuticals, Inc

2.45 *Questions & discussion*

2.50 **Virus Like Particle (VLP) based vaccines for pandemic and seasonal influenza**

- Progress on clinical development and manufacturing solution for our VLP based pandemic and seasonal vaccines will be presented
- The ability of our VLP and manufacturing platforms to enable regional production of vaccines will be described

**Dr Rahul Singhvi**, President & CEO, Novavax, Inc

3.10 *Questions & discussion*

3.15 **Panel discussion**

3.45 **Moderator's closing summary**

3.50 *Close of session followed by afternoon tea in the exhibition area*

FOLLOWED BY AFTERNOON PLENARY SESSION

OR | BREAKOUT SESSION

**Partnering workshop: Examining recent trends and deals to inform your business development strategy**

Highly interactive workshop for a maximum of 30 participants

11.40 **Moderator's introduction**

**Dr Karen J. Huebscher**, Global Head of Business Development & Licensing, Novartis Vaccines and Diagnostics

11.55 **Analyzing recent partnering trends in the vaccine sector**

- What degree of activity, and in which particular technology/application areas, can we expect to see in future?

**Dr Allan P. Jarvis**, Senior Vice President, Corporate Development, sanofi pasteur

12.25 *Questions & discussion*

**Case studies: Exploring the strategic drivers behind recent collaborations within the vaccine sector**

- Evaluation criteria: What were the specific values that attracted us in the first place and how do we plan to maintain and nurture them?**
- Successfully navigating the partnering process: How were the key decisions made at each step?**

12.30 **AstraZeneca - MedImmune, Inc**

**Drs Ben Machielse**, Executive Vice President, Operations, MedImmune, Inc  
**Beth Wensley**, Vice President, Project Management, MedImmune, Inc

1.05 *Questions & discussion*

1.15 *Buffet lunch in the exhibition area*

OR **Working Lunch**

2.25 **Big pharma-biotech**

**Dr Douglas J. Pon**, Assistant Vice President, Vaccine Licensing, Global Business Development, Wyeth Pharmaceuticals

2.55 *Questions & discussion*

3.05 **Partnering with an NGO**

**Carla Botting**, Director, Quality Management & Commercial Affairs, PATH Malaria Vaccine Initiative (MVI)

3.35 *Questions & discussion*

3.45 **Moderator's closing summary & final questions**

3.50 *Close of session followed by afternoon tea in the exhibition area*

FOLLOWED BY AFTERNOON PLENARY SESSION



THEN | AFTERNOON PLENARY SESSION

**How high will the vaccine safety ball bounce?**

- How are regulators and industry addressing safety concerns over vaccines in general, and novel adjuvants in particular?

4.30 **Chair's introduction**  
**The FDA Animal Rule: Theory versus practice**

- What are the barriers to overcome in using the Animal Rule to actually license a vaccine?
- What do the existing animal models really tell us about human disease, and vice-versa?
- How can interspecies differences in immune response be overcome in developing correlates of human protection?

**Robert V. House, PhD**, President, DynPort Vaccine Company, LLC, Frederick, MD

4.50 **Keynote address**  
**Evaluating vaccine safety: US FDA perspective**

- How has the evaluation of vaccine safety evolved?
- Pre- vs post-licensure safety requirements
- Challenges in evaluating the safety of novel adjuvants

**Dr Norman W. Baylor**, Director, Office of Vaccines Research & Review (OVR), CBER, US Food & Drug Administration

5.10 **Industry/regulator roundtable discussion**  
**Debating a pathway to licensure for novel adjuvants: What are the next steps?**

- Comparing the real and perceived risks versus benefits of novel adjuvants: How much immunomodulation is too much in the current regulatory environment?
- Adjuvant lifecycle management: What R&D strategies and tools can potentially improve the safety of adjuvants whilst not reducing their effectiveness?
- Exploring the latest generation of immunomodulators nearing the clinic (eg nanoemulsions): What are the potential risks and benefits of these technologies on the horizon from industry and regulator perspectives?

Panelists:  
**Dr Norman W. Baylor**, Director, Office of Vaccines Research & Review (OVR), CBER, US Food & Drug Administration  
**Heather L. Davis, PhD**, Executive Director, Pfizer Global R&D, Vaccines Research; Site Head, Ottawa Laboratories  
**Dr Gregory M. Glenn**, Chief Scientific Officer, Intercell USA, Inc  
**Michael L. Dekleva, PhD**, Senior Director, World Wide Regulatory Affairs, Vaccines/Biologics, Merck & Co, Inc

5.30 *End of day 1 followed by a themed cocktail reception in the exhibition area*

**REGISTER BEFORE FRIDAY 31ST OCTOBER TO SAVE \$200!**

MORNING PLENARY SESSION

How will you ensure that the key vaccine markets remain sustainable propositions for your organization long term?

**Influenza & biodefense vaccines: What long-term funding/commercial opportunities are available?**

9.00 **Chair's introduction**

**Alan S. Taggart**, Vice President, Government Project Management, MedImmune, Inc

9.10 **BARDA Keynote address**

**Defining the major points of focus: How are we coordinating with other stakeholders to rationalize the anti-biothreat portfolio and what does this mean in terms of funding opportunities for the vaccine industry?**

- The US Government, with HHS as the lead department, utilizes an enterprise system to manage the development, stockpiling, and infrastructure building of medical countermeasures (MCM) for preparedness against chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging diseases. BARDA is the lead HHS agency that manages the advanced development, establishment of initial stockpiles, and infrastructure building of domestic manufacturing of MCMs. The progress towards national preparedness policy goals, challenges in achieving these goals, and strategies to mitigate these challenges will be presented

**Dr Robin Robinson**, Director, Biomedical Advanced Research & Development Authority (BARDA), Office of the Assistant Secretary for Preparedness & Response (ASPR), US Department of Health & Human Services

9.35 *Questions & discussion*

9.40 **Public/private sector stakeholders' short presentations & roundtable discussion**

- How many players will the influenza vaccine market in general support, given its increasingly commoditized nature?
  - What is the balancing point?
- Can the pandemic influenza market survive without a pre-pandemic element?
- What is the current view of the value of H5N1 stockpiling specifically?
  - What should be done with current stockpiles nearing their expiry dates?
- What are the options for utilizing/converting spare manufacturing capacity?

- What is the latest progress towards developing a 'universal' influenza vaccine?
- What will be the next step in the influenza area - a quadrivalent vaccine?
- What is being done to engage more vaccine companies in the biodefense space, particularly the larger companies?

Panelists:

- Dr Robert Kadlec**, Special Assistant to the President for Homeland Security & Senior Director for Biological Defense Policy
- Dr Michael G. Kurilla**, Director, Office of BioDefense Research Affairs, Associate Director for BioDefense Product Development, DMID, NIAID, NIH, DHHS
- Dr Darrell R. Galloway**, Director, Joint Science & Technology Office, Chemical & Biological Defense Directorate, Defense Threat Reduction Agency, US Department of Defense
- Thomas E. Shrader, PhD, CFA**, Managing Director, Healthcare Research, Rodman & Renshaw, LLC
- Dr Ian Henderson**, Chief Scientific Officer, DynPort Vaccine Company, LLC, Frederick, MD

10.50 *Morning coffee in the exhibition area*

**Adult, adolescent and pediatric vaccines: How will vaccination schedules, and infrastructure in general, accommodate new products?**

11.30 **Chair's introduction**

**CDC perspective on evolving vaccine schedules and unmet needs**

**Anne Schuchat, MD, RADM**, US Public Health Service, Assistant Surgeon General, Director, National Center for Immunization & Respiratory Diseases, Centers for Disease Control & Prevention

11.45 **Roundtable discussion**

**Where next for novel pediatric vaccines?**

- How might they be accommodated into the current schedule, especially given current public perception issues? Example: How are the developers of the various Men. B vaccine candidates in late-stage development strategizing to meet the demands of the North American and global pediatric vaccine marketplaces?

Panelists:

- Dr Clement Lewin**, Head, Strategic Immunization Planning, Novartis Vaccines and Diagnostics
- Dr Lou Cooper**, Past President, American Academy of Pediatrics (AAP)
- Professor Steven J. Czinn**, Chair, Department of Pediatrics, University of Maryland School of Medicine

12.10 **Short presentations & roundtable discussion**  
**Vaccines for adult and adolescent markets: What is developing in terms of target opportunities for the industry, and also the challenges in marketing and distributing these vaccines?**

- Case studies: Exploring the ongoing roll-out of HPV vaccines worldwide and the evolution of adult and adolescent vaccination schedules
  - How is the debate regarding the ethics of HPV vaccination evolving on a global scale, and what does this mean for the commercial prospects of emerging vaccine candidates such as chlamydia and herpes?
  - Case study: Diamyd - curing diabetes
  - Addressing the key remaining challenges in installing the necessary infrastructure to conduct adequate post-market surveillance of adults and adolescents
  - 'Bundling' of vaccines to make schedules more efficient, particularly for the adult population: What initiatives are underway, and where do the authorities and industry see possibilities in future?
- Speakers:
- Elisabeth Lindner**, CEO & President, Diamyd Medical AB
  - Dr Mark Feinberg**, Vice President, Policy, Public Health & Medical Affairs, Merck Vaccine Division
  - Dr Luc Hessel**, Executive Director, Policy Affairs, Europe, sanofi pasteur MSD

12.50 *Buffet lunch in the exhibition area*

OR **Working Lunch**

**How should the concept of post-marketing surveillance in the context of an emergency biodefense response evolve?**  
*(Very informal, highly interactive session for a maximum of 12 participants)*

FOLLOWED BY YOUR CHOICE OF 3 PARALLEL BREAKOUT SESSIONS:

FOCUS SESSION 1

**Cell culture manufacturing and beyond: How are next-generation manufacturing technologies performing in the clinic?**

- Are we seeing incremental improvements or major steps forward in terms of cost savings and increased yield/speed of production?

2.00 **Moderator's introduction**

**Dr Ronald W. Ellis**, Senior Vice President & Chief Technical Officer, NasVax Ltd, Israel

**Case studies assessing the pros and cons of emerging technologies in clinical development: What regulatory and product development challenges remain? How viable will they be in practice within a regulatory framework?**

2.10 **H5N1 vaccines; a comparison of cell culture and traditional manufacturing methods**

- Clinical performance versus homologous and heterologous H5N1 strains
  - Yield and speed of production
  - Impact on potential pandemic strategies
- Hartmut J. Ehrlich, MD**, Vice President, Global R&D, Baxter BioScience

2.30 *Questions & discussion*

2.35 **FluBlok: A next generation influenza vaccine manufactured in insect cells**

- FluBlok: Recombinant hemagglutinin - a revolutionary or evolutionary product?
- Advantages and challenges in using a novel cell substrate
- Update on FluBlok clinical development

**Drs Manon Cox**, Chief Operating Officer, Protein Sciences Corporation

2.55 *Questions & discussion*

3.00 **Plant-based manufacturing**

- Capacity, timescale and cost efficiency of a plant-based production platform with a focus on fully contained manufacturing
- Addressing issues related to the quality of plant-made targets (biochemical as well as immunological)

**Dr Vidadi Yusibov**, Executive Director, Fraunhofer Center for Molecular Biotechnology

3.20 *Questions & discussion*

3.25 **Panel discussion**

- In recent years, why have we not seen the same degree of manufacturing technology and process innovation in the vaccine area as we have in the monoclonals field, for example?
  - Are the key barriers to innovation regulatory-, product- or science-related and how can the industry help address them to drive widespread acceptance of these novel approaches?

3.45 **Moderator's closing summary**

3.50 *Close of session followed by afternoon tea in the exhibition area*

FOLLOWED BY AFTERNOON PLENARY SESSION

OR | FOCUS SESSION 2

**Update on non-oncology therapeutic vaccines in clinical development**

2.00 **Moderator's introduction**

**Dr Keith Gottesdiener**, Vice President & Head of Clinical Vaccines & Infectious Diseases, Merck Research Laboratories

**Case studies: Delivering the latest clinical data and ongoing clinical development and regulatory strategies for leading candidates in development in a number of application areas**

2.10 **Diamyd - treating autoimmune diabetes**

**Elisabeth Lindner**, CEO & President, Diamyd Medical AB

2.30 *Questions & discussion*

2.35 **Developing an effective vaccine for smoking cessation**

- Smoking is an addiction that is the single most preventable cause of

mortality and morbidity in the world. Nicotine addiction is very difficult to treat and current therapies are modestly effective in the long term, at best

- Many current therapies are also associated with significant side effects
- Vaccines for use as an aid to smoking cessation are a new innovative class of therapeutics that have the potential of helping smokers quit and remain abstinent, without the undesirable side reactions associated with small molecules
- NicVAX is the leading vaccine candidate to treat nicotine addiction that demonstrated promise in a phase II proof-of-concept trial

**Raafat E. F. Fahim, PhD**, President & CEO, Nabi Biopharmaceuticals

2.55 *Questions & discussion*

3.00 **Development of AFFITOPE vaccines for Alzheimer's disease**

- The AFFITOPE concept - why use AFFITOPES of A<sub>n</sub> rather than A<sub>n</sub> itself? Implications for vaccine design, composition, safety and efficacy
  - POC data in animal models of AD: Assessing the effect of targeting the N-terminus of A<sub>n</sub> with two different AFFITOPE vaccines
  - First-in-man studies of AFFITOPE vaccines AD01 and AD02: Early data on their safety, tolerability and immunogenicity in Alzheimer's patients
- Professor Dr Achim Schneberger**, Head of Clinical Development, AFFIRIS GmbH

3.20 *Questions & discussion*

3.25 **Panel discussion**

**What might the pathway to approval for these new applications look like?**

- How will they be regulated? (Which branch of the FDA would be responsible?)

Panelist:

**Peter Zerhouni**, Director of Business Development, Diamyd Medical AB

3.45 **Moderator's closing summary**

3.50 *Close of session followed by afternoon tea in the exhibition area*

FOLLOWED BY AFTERNOON PLENARY SESSION

OR | BREAKOUT SESSION

**Executive regulatory briefing**

A series of presentations and interactive discussions designed to provide an executive summary of key emerging regulatory legislation and guidelines from around the globe, pitched at a strategic level to provide insight into potential implications for your business

Highly interactive workshop for a maximum of 30 participants

2.00 **Moderator's introduction**

**The regulatory pathways to gaining marketing approval in Europe: Reaping the benefits of making the right strategic choice**

- An introduction to the approval procedures in Europe: Centralized, Mutual Recognition, Decentralized and National
- The scope of the Centralized procedure: Does your company have a choice on the route to take?
- The importance of a regulatory strategy: The pro's and con's of the different routes
- Centralized vs. Mutual Recognition vs. Decentralized vs. National:

Examples of strategies available

**Dr David Kirke**, Senior Consultant, ERA Consulting Group

2.25 **Clarifying the impact of key recent European legislation on the vaccine area**

- How to capitalize on the potentially significant benefits in terms of cost and time savings provided by the Vaccine Antigen Master File (VAMF)
  - Navigating the Pediatric Investigation Plan (PIP) filing process: Vaccine company experiences and lessons learned to date
- Awaiting final confirmation: **Kimber L. Poffenberger, PhD**, Vice President, Regulatory Affairs, Intercell USA, Inc

2.45 *Questions & discussion*

2.55 **What is the latest information on the development of regulatory systems for companies seeking to conduct clinical development and/or license products in the Far East?**

- Overview of registration requirements for China, Taiwan, Korea, Japan, and India for vaccines, including clinical study requirements
  - Clarification of the latest developments in Chinese regulatory guidelines and legislation relating to vaccines
- Michael L. Dekleva, PhD**, Senior Director, World Wide Regulatory Affairs, Vaccines/Biologics, Merck & Co, Inc

3.15 *Questions & discussion*

3.20 **A summary of the latest developments in the regulatory environment for influenza vaccines and related technologies**

*Speaker to be announced*

3.40 *Questions & discussion*

3.45 **Moderator's closing summary**

3.50 *Close of session followed by afternoon tea in the exhibition area*

FOLLOWED BY AFTERNOON PLENARY SESSION

THEN | AFTERNOON PLENARY SESSION

**Reassessing the vaccine community's R&D approach to the hardest targets**

- What future directions should public and private sector stakeholders alike take in areas such as HIV?

4.30 **Presentations and panel discussion**

- What lessons may be taken from recent setbacks in areas such as HIV?
  - What will be the long-term impact on other adeno-vectored vaccines, and viral vectored vaccines in general?
  - Have we adequately tested CMI in HIV vaccines yet?
  - To what degree will the pendulum swing back to consideration of antibody response to preserved epitopes?
  - Should the community concentrate solely on funding basic research in the most difficult target areas such as HIV, or on getting into the clinic, or on a blend of the two?
- If the latter, what is the ideal balance moving forwards, given the economic pressure on vaccine companies to proceed to human trials as quickly as possible?
- In the context of emerging infectious diseases that are new to science (eg SARS) how much use is basic research, or are we better served by proceeding to human studies? How do you balance risk-benefit in these cases?

- Alphavirus-vectored vaccine approaches: the benefits of self-replicating RNA
    - Mimicking live virus infection with single round infectious particles
    - RNA vectors versus DNA
    - Application to HIV and beyond
  - How are the various stakeholders' philosophies evolving regarding R&D approaches to the other two members of the 'Big 3' - TB and malaria?
- Moderator:
- Carl W. Dieffenbach, PhD**, Director of the Division of AIDS (DAIDS), National Institute for Allergies & Infectious Diseases (NIAID), NIH
- Speakers:
- Dr John W. Shiver**, Vice President, Worldwide Basic Research Franchise Head, Vaccines, Merck Research Laboratories
  - Christian Mandl, MD, PhD**, Vice President & Global Head of Virology, Head of Research, US, Novartis Vaccines and Diagnostics, Inc
  - Dr Jill Gilmour**, Senior Director, Clinical Immunology, International AIDS Vaccine Initiative

5.30 *End of day 2 followed by a themed cocktail reception in the exhibition area*



Driving Progress

REGISTER BEFORE FRIDAY 2ND NOVEMBER TO SAVE \$200!

AGENDA UPDATES | SPEAKER UPDATES | ON-LINE REGISTRATION | LATEST EVENT NEWS

www.phacilitate.co.uk/wv

MORNING PLENARY SESSION

**Worldwide vaccine market sustainability: Capitalizing on the business opportunities presented by unmet needs on a global scale**

9.00 **Chair's introduction**  
**Dr Una S. Ryan**, Former CEO of AVANT Immunotherapeutics

9.05 **Global public health opportunities for vaccines and biologics companies**

- This is an unprecedented time in history for potential funding available for research, development, procurement, and delivery of vaccines and biologics on a global scale
- Yet the present global credit crunch is distorting venture capital markets just now, so many exciting technologies and companies are starved for capital
- Biologics and vaccines companies who position and act globally, and creatively think through their capital and growth strategies, can possibly tap into these streams of funding
- However, they'll need to think a bit differently about these opportunities, because many of these funders have philanthropic, economic development and/or social missions (rather than straight profit motivations)

**Bill Helming**, Vice President, Biodefense & Public Health Practice, PRTM Management Consultants LLC

9.25 *Questions & discussion*

9.30 **Analyst's perspective**  
**What are our current assessments regarding the value of key second-tier nation vaccine markets?**

- China
- India
- Korea
- Russia

*Speaker to be announced*

9.50 *Questions & discussion*

9.55 **Industry Keynote Address**  
**Pharma R&D strategies integrating small molecules, biologicals and vaccines:**

- Multiple platforms provides flexibility for design of new therapies against new identified disease targets
- Maximizes opportunities to meet the demands of the changing global health care environment and contribution from developed and emerging markets
- Emerging role of vaccines in management of both traditional bacterial infections and antibiotic resistant bacterial infections
- Growing role of vaccines in disease management of infant to aging patient groups

**Dr Mikael Dolsten**, President, Research & Development, Wyeth Pharmaceuticals, Senior Vice President, Wyeth Corporation

10.15 *Questions & discussion*

10.20 **Case study and panel discussion**  
**Exploring a public-private partnership model for advancing development of TB vaccines for the world: Oxford Emergent Tuberculosis Consortium (OETC)**

Panelists:  
**Wendy Taylor**, Vice President of Strategy & Operations, BIO Ventures for Global Health  
**Dr Helen McShane**, University of Oxford  
**Dr Stephen Lockhart**, Senior Vice President, Product Development, Emergent Biosolutions

10.50 **R&D update: Delivering the latest results from advanced clinical trials of malaria vaccines**

- What are the ongoing product development strategies for these candidates?
- What can be done to ensure that the public health environment and infrastructure are prepared in developing nations to a sufficient level that a malaria vaccine would be entering a viable marketplace upon achieving regulatory approval?

**Dr Tonya Villafana**, Director, Portfolio Management, PATH Malaria Vaccine Initiative (MVI)

11.15 *Questions & discussion*

11.15 *Morning coffee in the exhibition area*

11.55 **NGO-industry-regulator presentation and panel discussion**

- Case study: Multi-valent pneumococcal vaccine - exploring the challenges and the role of public-private partnering in the clinical and product development of a truly global vaccine
- How to make vaccines more affordable for the global marketplace while retaining the business case for industry?
  - Exploring the ongoing evolution of public-private collaborative development engines: Can more be done to assist industry with the clinical development and manufacture of these vaccines, thereby potentially reducing costs and price?
- As novel vaccines in general become technically more complex (eg adjuvanted sub-unit vaccines) can the additional production expense be supported in the developing world context, or do we need to focus on affordability from the bench? (To what extent is this possible?)
- How are regulatory pathways in the US and Europe evolving to enable the development of vaccines predominantly for the developing and undeveloped worlds?
- Case study: Priority Review Vouchers: A revolutionary change for global health innovation?
  - Under a new FDA program, a company that successfully develops a product that treats or prevents a neglected tropical disease can now earn a priority review for a future product of its choice
  - The vouchers, which can be traded and sold, may shave 6 or more months off the FDA review time and be worth hundreds of millions of dollars
  - This intriguing new incentive program is capturing the attention of biotech, investors and big pharma alike
  - Explore the value of this creative incentive and the likelihood that it will motivate companies to start up new global health R&D programs

Panelists:  
**Dr Norman W. Baylor**, Director, Office of Vaccines Research & Review (OVR), CBER, US Food & Drug Administration  
**Dr Suresh Jadhav**, Executive Director, Serum Institute of India Ltd  
**Dr John Boslego**, Director, Vaccine Development Global Program, PATH  
**Wendy Taylor**, Vice President of Strategy & Operations, BIO Ventures for Global Health

1.05 *Buffet lunch in the exhibition area*

FOLLOWED BY YOUR CHOICE OF 3 PARALLEL BREAKOUT SESSIONS:

FOCUS SESSION 1

**Employing novel characterization tools and techniques to improve decision-making at each stage of the R&D pipeline**

2.15 **Moderator's introduction**  
**Preclinical case study: Harnessing novel translational medicine tools and techniques to accelerate progress towards First-in-Man studies in the vaccine field**

- Which preclinical models correlate best to humans?
  - How well is data from ex vivo studies correlating to humans in comparison to animal data? Is there evidence that this data can have value in developing vaccines?

**Dr Michael V. Callahan**, Program Manager, Rapid Vaccine Assessment (RVA), Defense Advanced Research Projects Agency (DARPA)

2.40 *Questions & discussion*

**Clinical case studies**  
**How are novel high-throughput assays improving clinical trial design and decision making through the phases?**

- Addressing the key challenges
  - How do you decide which assay to choose with regulatory acceptance in mind?
  - How are companies dealing with the technical challenges of low-throughput T-cell assays when required as part of immunogenicity measures?
  - How can you overcome the lack of technical and regulatory standardization?
  - Which assays are the most relevant, in particular with regard to measuring non-humoral responses, and with regard to reproducibility?

2.45 **Correlates of protection for influenza**

- Limitations of currently used correlates (HI and SRH)
- Pseudotype neutralization for pandemic flu and beyond
- Protection from mucosal and cellular immunity
- Translational medicine to define new correlates of protection

**Christian Mandl, MD, PhD**, Vice President & Global Head of Virology, Head of Research, US, Novartis Vaccines and Diagnostics, Inc

3.05 *Questions & discussion*

3.10 **The ABC of therapeutic vaccination: Antigens, adjuvants and immunological monitoring**

- Development of therapeutic vaccination against chronic disease
- Furthest developed therapeutic HCV vaccine, strong evidence for antiviral activity
- Pioneering vaccine design: Cocktail of synthetic peptides tailored to match human HLA, synthetic IFN-gamma/T cell promoting adjuvant
- In-depth immunological characterization by ELISpot, HLA-tetramers and lymphoproliferation
- Intercell technology platforms (T cell epitope and adjuvant discovery) provide rich pipeline for development of second generation therapeutic vaccines with further enhanced HLA coverage and increased immunogenicity

**Dr Christoph S. Klade**, Vice President, Technology Development & Clinical Immunology, Intercell AG

3.30 *Questions & discussion*

3.35 **Case study & panel discussion**

- Case study: Gardasil®: Exploring the successful development of a vaccine using modern lab techniques and technologies
  - Identify and address the critical questions
    - Vaccine components
    - Required immune response
    - Clinical assays
  - What lessons are there for other vaccine developers?

**Dr Janine T. Bryan**, Senior Research Fellow & HPV Lead, Department of Vaccines Basic Research, Merck Research Laboratories

4.05 **Moderator's closing summary**

4.10 *Close of the Phacilitate Vaccine Forum Washington 2009 followed by afternoon tea in the exhibition area*

OR FOCUS SESSION 2

**Update on therapeutic cancer vaccines in clinical development**

2.15 **Moderator's introduction**  
**Examining the 20-year history of therapeutic cancer vaccines**

- Analyzing set backs and progress to date: What trends have we seen and what lessons can be taken forward to assist in the ongoing development of these products?

**Professor Angus Dalgleish**, Professor of Oncology, St George's, University of London & Research Director, Onyvx Limited

2.25 **Big pharma perspective**  
**How do we envisage the field progressing over the short-, mid- and long-terms?**

**Dr Karen J. Huebscher**, Global Head of Business Development & Licensing, Novartis Vaccines and Diagnostics

2.45 *Questions & discussion*

**Case studies: Analyzing the latest clinical data from leading cancer vaccine candidates in late-phase trials**

- What are current expectations in terms of time-to-market?
- Addressing ongoing regulatory concerns: How is the pathway to market evolving?

2.50 **Progress in the development of Sipuleucel-T for the active immunotherapy of prostate cancer**

- Introduction to prostate cancer
- Background on Sipuleucel-T development
- Clinical trial results
- Discussion of regulatory milestones and path to market

**Dr David L. Urdal**, CSO, Dendreon Corporation

3.10 *Questions & discussion*

3.15 **Moving beyond current paradigms for clinical trial design and combination therapies**

- Data are emerging from recent clinical trials involving several different cancer vaccines contrasting "tumor response" (Response Evaluation Criteria in Solid Tumors) criteria with "patient response" in the manifestation of increased patient survival post-vaccine therapy
- There are several strategies in which cancer vaccines can be exploited in combination with other therapeutic modalities which are quite unique, when compared with "conventional" combination therapies
- Several clinical studies with recombinant poxvirus vaccines have shown evidence of clinical benefit, most importantly, increased survival

**Dr Jeffrey Schlom**, Chief, Laboratory of Tumor Immunology & Biology, Center for Cancer Research, National Cancer Institute

3.35 *Questions & discussion*

3.40 **Panel discussion**  
**How do you make development decisions for products in a novel class with no 'roadmap'?**

- Looking at the pipeline phase-by-phase, how can we move forward without this map: What is the analogue to classical clinical development for cancer vaccines?
- How can we realize the potential of various novel immune modulators (antibodies, checkpoint inhibitors, etc) to boost immune response to cancer vaccines?
- Can immunoassays really be trusted for clinical development decision-making in the cancer vaccine area?
  - What further standardization is required in this area to provide really meaningful results?

Panelist:  
**Dr Charles G. Drake**, Assistant Professor of Medical Oncology, Immunology & Urology, Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University

4.05 **Moderator's closing summary**

4.10 *Close of the Phacilitate Vaccine Forum Washington 2009 followed by afternoon tea in the exhibition area*

OR BREAKOUT SESSION

**Global health as a 2-way street: What opportunities are available to both Eastern and Western vaccine companies to reduce costs and access novel markets and populations?**

Highly interactive workshop for a maximum of 30 participants

2.15 **Moderator's introduction**  
**Wendy Taylor**, Vice President of Strategy & Operations, BIO Ventures for Global Health

2.20 **Western company perspective**  
**Case study: In what scenarios are Eastern manufacturing opportunities of potential benefit to Western vaccine companies?**

- Assessing the pros and cons in comparison to a less international approach

**Shankar Musunuri, PhD, MBA**, Senior Director & Strategic Product Leader, Wyeth Biotech

2.45 *Questions & discussion*

**Eastern company perspectives**  
**What are our specific strategic goals moving forwards, how are we evolving our business models to achieve them, and what opportunities are there for partnering with Western counterparts?**

- Penetrating Western markets: Meeting the challenge of adhering to Western regulatory requirements
- Developing innovative vaccines to address neglected diseases closer to home: To what extent are expectations regarding product quality changing in second-tier nations as per capita disposable income increases and how is this impacting our business models?

2.50 **Indian company perspective**  
**Building a global vaccine company**

- Challenges of building a global vaccine company in India
- Historical context
- Challenges to expand markets
  - Business
  - Technical
  - Regulatory
- Opportunities
  - Partnerships
  - Public markets

**Narender Dev Mantena**, Senior Vice President, Strategic Business Development, Biological E. Limited

3.10 *Questions & discussion*

3.15 **Chinese company perspective**  
*Speaker to be announced*

3.35 *Questions & discussion*

3.40 **Panel discussion**  
**In what timeframe will vaccine manufacturers be able to meet evolving bioequivalence requirements and to what degree will this impact the global vaccine sector?**

4.05 **Moderator's closing summary**

4.10 *Close of the Phacilitate Vaccine Forum Washington 2009 followed by afternoon tea in the exhibition area*

**Phacilitate calendar of events**

**Phacilitate Cell & Gene Therapy Forum 2009**  
 Running concurrently with the Washington Vaccine Forum - shared networking!  
 26-28 January, The Grand Hyatt Washington, DC  
[www.phacilitate.co.uk/cgtherapy](http://www.phacilitate.co.uk/cgtherapy)

**Phacilitate Vaccine Forum Barcelona 2009**  
 22-24 June, The Fira Palace Barcelona  
[www.phacilitate.co.uk/barcelona](http://www.phacilitate.co.uk/barcelona)

**Phacilitate Active Immunotherapeutics Forum 2009**  
 22-24 June, The Fira Palace Barcelona  
[www.phacilitate.co.uk/barcelona](http://www.phacilitate.co.uk/barcelona)

CO-LOCATED IN 2009



# Sponsorship and exhibition opportunities

The combined Washington Vaccine Forum 2009 and Cell & Gene Therapy Forum 2009 provides an unparalleled networking and profile-raising opportunity to companies targeting these sectors. All networking activities are shared in a central exhibit area, giving you a great chance to meet with numerous senior level R&D, regulatory, business development, manufacturing executives all under one roof and in just three days!

**"It really was a great event. I look forward to exhibiting again next year. Very informative and in a great setting that encouraged open dialogue and networking"**

Megan Barth, Director of Sales,  
Pharmaceutical & Biotechnology, Sterigenics


**"The Cell and Gene Therapy Forum / Vaccine Forum held in January 2008 was a very successful event for the ERA Consulting Group. Not only was this a unique opportunity for us to have meetings with many of our current clients, but we also successfully secured 4 new clients at this event. ERA will certainly be attending the 2009 event."**

Paul Cronin, Business Development Manger, ERA Consulting Group

As you can see, the best booth spaces are running short. To receive more information on exhibiting, or to find out about available sponsorship options (ranging from full event, workshop and cocktail reception packages to minor sponsorships, such as conference documentation, delegate bags, event stationery and documentation inserts) please don't hesitate to contact David McCall (t: +44 (0)20 7839 6151, or e: david@phacilitate.co.uk).

**AND REMEMBER! As an exhibitor at this meeting, you will have equal access to delegates and speakers from both the Washington Vaccine Forum 2009 and the Cell & Gene Therapy Forum 2009 - over 500 senior life science executives with the authority to impact your business!**

[www.phacilitate.co.uk/wv](http://www.phacilitate.co.uk/wv)



## Exhibitors:

- Booth 5 Eden Biodesign
- Booth 6 WuXi AppTec
- Booth 7 Bridge Laboratories
- Booth 8 Progenitor Cell Therapy
- Booth 11 Accelovance
- Booth 12 MGlas
- Booth 13 Worthington Biochemical Corporation
- Booth 15 Angel Biotechnology PLC
- Booth 16 GE Healthcare
- Booth 17 BD Medical - Pharmaceutical Systems
- Booth 18 Pall Life Sciences
- Booth 19 Cobra Biomanufacturing
- Booth 20 DynPort Vaccine Company LLC, A CSC Company

- Booth 21 Beardsworth Consulting Group
- Booth 22 Covance Research Products
- Booth 23 PRTM
- Booth 24 Aldevron
- Booth 25 BioLife Solutions
- Booth 28 Novozymes Biopharma
- Booth 29 Eufets
- Booth 30 Diamyd Medical
- Booth 33 ERA Consulting
- Booth 34 Lonza
- Booth 35 Ichor Medical Systems
- Plus table-top exhibitors
- BioSpherix Ltd
- LifeCyte, Inc
- Sterigenics, Inc

## Gold sponsor:

Our passion is to help to customers re-imagine life

sciences, unlock nature's secrets and develop medicines. We offer a wide range of products and services for chromatography and membrane separations, from lab to production scales. Our products are used in the manufacture of over 90 percent of all FDA-approved biopharmaceuticals on the market. Products/Services: Filtration products; a comprehensive range of ULTA™ normal flow products, Hollow Fiber cartridges, Kwick™ cassettes and AKTAcrossflow™ a fully automated filtration system. AKTAdesign™ protein purification systems in different scales and configurations. BioProcess™ media for security of supply, robust performance, and regulatory support including MabSelect™ for MAb purification and Capto™ ion exchangers for high productivity. Cell technologies; generic automated and integrated processing and storage solutions such as Ficol-Paque™ PREMIUM, Percoll™ PLUS and BioArchive® System. Wave Biotech products; disposable bioprocess equipment including Wave Bioreactor®, Wave Mixer®, and Sterile Tube Fuser®. ReadyToProcess; An integrated product platform of ready-to-use and single-use solutions for all aspects of bioprocessing - upstream and downstream.

[www.gehealthcare.com](http://www.gehealthcare.com)



## Silver sponsors:



Management Consultants

Since 1976, PRTM has created a competitive advantage for its clients by changing the way companies operate. PRTM management consultants work with senior executives to develop and implement innovative operational strategies that deliver breakthrough results. The firm is a leader in operational strategy, supply chain, product development, and customer management. PRTM has 16 offices worldwide and serves major industry and government sectors. [www.prtm.com](http://www.prtm.com)



Diamyd Medical - curing diabetes.

The Company's mission is to contribute in the global effort to find this cure and to eliminate complications from the disease. Accordingly, the Company currently develops therapeutics from two independent platform technologies. One of these platforms relies on the GAD65 molecule and the other on a viral delivery system of proteins to nervous tissue (Nerve Targeted Drug Delivery System, NTDDS). Therapeutics for conditions other than diabetes are also being developed using these platforms.

Diamyd Medical's furthest developed products are the vaccine Diamyd® for type 1-diabetes (Phase III) and the vaccine Diamyd® for LADA (Phase II). GAD65 is a major autoantigen in autoimmune diabetes and both of the Diamyd® vaccines are intended to induce immunotolerization.

Diamyd is a Swedish public company listed on the OMX Nasdaq Nordic list. The company has headquarters in Stockholm, Sweden and offices in Pittsburgh, Pennsylvania.

[www.diamyd.com](http://www.diamyd.com)



Filtration. Separation. Solution. sm

The life sciences industry is both driven and united by its need for speed to market, product reliability and economics. Pall's leading edge filtration, separation and purification technologies and services play an essential and pivotal role in this industry's ability to achieve these goals. Pall direct and tangential flow filtration technologies are used for biomass removal, clarification, particulate and bioburden reduction, prefiltration, sterile filtration of liquids and gases, mycoplasma, prion and virus clearance, endotoxin and DNA removal, and biomolecule purification and concentration. Products scale from small laboratory devices to production systems and instrumentation. Pall has industry leading membrane chromatography products, chromatography columns, packing and control systems ranging from laboratory and small pilot to fully engineered state of the art columns with fully automated axial compression packing up to 2.3 meters, and BioSeptra® media for ion exchange, affinity, hydroxyapatite, hydrophobic charge induction and size exclusion chromatography. Pall offers process development and validation services together with pre-inspection reviews, as well as troubleshooting consultancy, training, contamination analysis and other technical assistance. Additional services are multi-step chromatography purification development, target and impurity tracking, purification optimization and custom affinity sorbents. [www.pall.com/biopharm](http://www.pall.com/biopharm)



## Bronze sponsors:



DynPort Vaccine Company LLC, a CSC company, is a technology integrator providing solutions that protect humanity from emerging threats. DVC has comprehensive experience in the advanced development of biodefense biologics, including live attenuated vaccines, recombinant vaccines, therapeutics, therapeutic polyclonal antibodies and alternative vaccine delivery systems. The DVC pipeline includes botulinum polyclonal antibodies, butyrylcholinesterase ("BioScavenger"), and vaccines for plague, tularemia, botulinum neurotoxin and seasonal and pandemic influenza. For more information and current career opportunities, visit [www.csc.com/dvc](http://www.csc.com/dvc).



Emergent BioSolutions Inc. is a leading biopharmaceutical company dedicated to one simple mission - **to protect life**. We develop, manufacture and commercialize immune related biologics, vaccines and biotherapeutics that assist the body's immune system to prevent or treat infectious and other life threatening diseases. Our marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Our product pipeline also includes: two "next generation" anthrax vaccines, two anthrax therapeutics (immunoglobulin and monoclonal), two botulinum vaccines and a botulinum therapeutic, an oral typhoid vaccine, a next generation tuberculosis vaccine, a hepatitis B immunotherapy, and a chlamydia vaccine. [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com)

## Wi-fi sponsor:



NasVax engages in the development of improved vaccines. Its platform technology is based on proprietary polycationic sphingolipid-derived molecules that serve both as a potent adjuvant for stimulating enhanced immune responses via the Th1 and Th2 pathways as well as an efficient delivery system. The technology enables intranasal as well as intramuscular vaccine administrations and also may be applied to augment the bioactivity of established adjuvants and cytokines. The Company's lead program is an improved influenza vaccine (Phase 1/2a), with other programs for hepatitis B, avian flu and anthrax vaccines. [www.nasvax.com](http://www.nasvax.com)

FOR ALL THE LATEST INFORMATION VISIT

[www.phacilitate.co.uk/wv](http://www.phacilitate.co.uk/wv)